Despite insufficient evidence, the panel suggests screening patients, especially if splenectomised and/or affected by sickle cell disease, testing the most common biomarkers of the prothrombotic state (serum homocysteine, antiphospholipid antibodies, protein C, protein S, resistance to activated protein C, antithrombin), before starting hormone replacement therapy. This evidence concerns the gene PROC and sickle cell disease.